Subject(s)
Atrial Fibrillation/complications , Coronary Stenosis/pathology , Coronary Vessels/pathology , Embolism/pathology , Tomography, Optical Coherence , Aged , Anticoagulants/therapeutic use , Atrial Fibrillation/diagnosis , Coronary Angiography , Coronary Stenosis/etiology , Coronary Stenosis/therapy , Embolism/etiology , Embolism/therapy , Humans , Male , Percutaneous Coronary Intervention/instrumentation , Platelet Aggregation Inhibitors/therapeutic use , Predictive Value of Tests , Renal Artery Obstruction/diagnosis , Renal Artery Obstruction/etiology , Renal Artery Obstruction/therapy , Stents , Treatment OutcomeABSTRACT
We report an incidentally noted aneurysm in the left renal artery in a 60-year-old woman. Repair was recommended due to the size of the aneurysm and the patient's history of hypertension. The aneurysm was located in a bifurcation lesion, and angulation at the site was approximately 90 degrees. We were able to successfully exclude the aneurysm, however, with a balloon-expandable covered stent. This suggests that balloon-expandable covered stents offer excellent delivery and precise deployment, even in cases where complex anatomical issues are involved.
Subject(s)
Aneurysm/surgery , Angioplasty, Balloon/instrumentation , Coated Materials, Biocompatible , Renal Artery , Stents , Aneurysm/diagnostic imaging , Angiography , Female , Follow-Up Studies , Humans , Middle Aged , Prosthesis Design , Tomography, X-Ray ComputedSubject(s)
Chromosomes, Human, X , Leukemia/genetics , Sex Chromosome Aberrations , Acute Disease , Aged , Humans , MaleABSTRACT
A 47-year-old man was diagnosed with non-Hodgkin's lymphoma (NHL) follicular B-cell type (stage IVB). Although partial remission was observed after the administration of several combination chemotherapeutic agents, no more improvement was observed. After we finished the FND (fludarabine, mitoxantrone, dexamethasone) regimen, the patient's status improved. After the administration of the FND regimen, thrombocytopenia developed, and the platelet count did not recover to previous levels. After rituximab was administered for the treatment of thrombocytopenia, the platelet count recovered. Then we combined fludarabine and rituximab for the treatment of NHL. Although fludarabine was administered, the platelet count did not decrease when combined with rituximab. In the discussion, we analyze the characteristics and the treatment outcome of the thrombocytopenia induced by fludarabine reviewed in the literature.
Subject(s)
Antibodies, Monoclonal/therapeutic use , Lymphoma, Follicular/drug therapy , Thrombocytopenia/drug therapy , Vidarabine/analogs & derivatives , Vidarabine/adverse effects , Antibodies, Monoclonal, Murine-Derived , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Humans , Lymphoma, Follicular/complications , Male , Middle Aged , Rituximab , Thrombocytopenia/chemically induced , Thrombocytopenia/immunology , Thrombocytopenia/prevention & control , Treatment Outcome , Vidarabine/therapeutic useABSTRACT
Interferon (IFN) is one of several drugs effective in treating multiple myeloma (MM), and propagermanium is an IFN inducer. We report on 10 MM patients who were treated with propagermanium at doses from 10 to 40 mg. Two patients achieved complete remission (CR), two patients achieved partial remission (PR), and the condition of four patients was stable (stable disease, SD). After discontinuation of propagermanium, the status of MM progressed in two patients who were in SD and in two patients who had achieved PR. The administration of propagermanium was restarted in one patient resulting in a decrease in her paraprotein.
